

August 18, 2009

Kowa Co., Ltd.  
Mitsubishi Tanabe Pharma Corporation

**Licensing Agreements Concluded for the Development and Commercialization of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan and Indonesia**

Kowa Company, Ltd. (Nagoya, President & CEO: Yoshihiro Miwa), Taiwan Tanabe Seiyaku Co., Ltd. (Taipei, Taiwan) and P.T. Tanabe Indonesia, (Jakarta, Indonesia), consolidated subsidiaries of Mitsubishi Tanabe Pharma Corporation (Osaka, President Michihiro Tsuchiya), hereby announce that the companies have concluded agreements on exclusive development and commercialization licenses for Taiwan and Indonesia in regard to pitavastatin calcium (generic name, brand name in Japan: Livalo tablet), a hypercholesterolemia treatment agent.

As a new HMG-CoA reductase inhibitor that exhibits strong LDL cholesterol lowering action at low doses, pitavastatin is positioned as a strong statin, and due to many findings, apart from that excellent lipid abnormality improvement effect, other characteristics such as safety in long-term use, decreases in the occurrence of drug interactions and usefulness when patients have diabetes complication have also been confirmed. Kowa obtained manufacturing approval in Japan in July 2003 and sales of the drug started in September the same year. Sales of Livalo tablet in 2008 reached ¥34 billion.

Kowa is proactively promoting the development and commercialization of drugs overseas, aiming at the global expansion of its drug operations centered on pitavastatin. So far, Kowa has commenced sales of the drug in Korea and Thailand through other business partners and commenced sales in China in July this year through another business partner. In America, Kowa obtained marketing permission from the Food and Drug Administration (FDA) on August 3 this year, while the company is currently applying for marketing permission in 16 European countries.

Meanwhile, Mitsubishi Tanabe Pharma has Taiwan Tanabe and Tanabe Indonesia, overseas subsidiaries with solid operating bases in Taiwan and Indonesia, and is currently working on the promotion of overseas drug business expansion as one of the priority issues in its Medium Term Management Plan 08-10. The in-licensing of pitavastatin will enable the further strengthening of the product pipeline and operating bases in Asia.

The companies arrived at this agreement because both are confident of realizing the maximization of pitavastatin business based on the excellent marketing capabilities of Mitsubishi Tanabe Pharma's subsidiaries in the countries (MRs: more than 60 in Taiwan and more than 140 in Indonesia) and the strong synergies with their good performance, experience and existing drugs in the cardiovascular area.

Through this cooperative venture, Mitsubishi Tanabe Pharma and Kowa will continue to build a win-win relationship for both companies in the future and make efforts towards the further improvement of corporate value.

[Reference] Pitavastatin global development

Country or region name	Status	Launch (schedule)	Marketing partner
Japan	Launched	September 2003	Kowa Co., Ltd. Daiichi Sankyo Company, Limited
Korea	Launched	July 2005	Choongwae Pharma Corporation
Thailand	Launched	January 2008	Biopharm Chemical Co., Ltd.
China	Launched	July 2009	*1
USA	Approved	As soon as launch preparations are complete	*2
Europe	Under application	2010	*3
Canada	Application under preparation	2010 - 11	SOLVAY PHARMA, INC.

\*1 In China, Kowa is advancing the provision of information to medical institutions and doctors on the appropriate use of pitavastatin and conducting information gathering activities through Kowa (Shanghai) Pharma Consulting Co., Ltd., a wholly-owned subsidiary of Kowa.

\*2 Kowa plans to market pitavastatin in the USA through Kowa Pharmaceuticals America, Inc. (Alabama, USA), a wholly-owned subsidiary of Kowa. The company is also looking at an alliance with a strong co-promotion partner.

\*3 Kowa plans to market pitavastatin in Europe through Kowa Pharmaceutical Europe Co., Ltd. (Wokingham, UK), a wholly-owned subsidiary of Kowa, and a marketing alliance partner (Recordati: Milan, Italy).